Cannabinoid Treatment Significantly Reduces Fibromyalgia Pain And Improves Quality Of Life, New Tilray-Backed Study Finds
Tilray Medical, a division of Canadian cannabis giant Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY) announced on Monday a new scientific publication supported by Tilray Medical titled, Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS). The study, consisting of patients with an average age of 52 years, examines the real-world impact of cannabinoid treatments on patients with fibromyalgia (FM) under the guidance of healthcare providers. The study revealed improvements in pain levels, sleep quality, and overall well-being for patients with fibromyalgia.
